BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kay DM, Langfelder-schwind E, Decelie-germana J, Sharp JK, Maloney B, Tavakoli NP, Saavedra-matiz CA, Krein LM, Caggana M, Kier C; the New York State Cystic Fibrosis Newborn Screening Consortium. Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening: Very High IRT in Newborn CF Screening. Pediatr Pulmonol 2015;50:771-80. [DOI: 10.1002/ppul.23222] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Sinclair G, McMahon V, Schellenberg A, Nelson TN, Chilvers M, Vallance H. Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia. Int J Neonatal Screen 2020;6:46. [PMID: 33073036 DOI: 10.3390/ijns6020046] [Reference Citation Analysis]
2 Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-gaudelus I, Blau H, Gartner S, Mccolley SA. Diagnosis of Cystic Fibrosis in Screened Populations. The Journal of Pediatrics 2017;181:S33-S44.e2. [DOI: 10.1016/j.jpeds.2016.09.065] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
3 Wallis C. Diagnosis and Presentation of Cystic Fibrosis. Kendig's Disorders of the Respiratory Tract in Children. Elsevier; 2019. pp. 769-776.e2. [DOI: 10.1016/b978-0-323-44887-1.00050-x] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Hughes EE, Stevens CF, Saavedra-Matiz CA, Tavakoli NP, Krein LM, Parker A, Zhang Z, Maloney B, Vogel B, DeCelie-Germana J, Kier C, Anbar RD, Berdella MN, Comber PG, Dozor AJ, Goetz DM, Guida L Jr, Kattan M, Ting A, Voter KZ, van Roey P, Caggana M, Kay DM; New York State Cystic Fibrosis Newborn Screening Consortium. Clinical Sensitivity of Cystic Fibrosis Mutation Panels in a Diverse Population. Hum Mutat 2016;37:201-8. [PMID: 26538069 DOI: 10.1002/humu.22927] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
5 Savant AP, McColley SA. Pediatric Pulmonology year in review 2015: Part 4. Pediatr Pulmonol 2016;51:754-65. [PMID: 27171478 DOI: 10.1002/ppul.23470] [Reference Citation Analysis]
6 Caggana M. Newborn screening for cystic fibrosis: can one algorithm fit all? Expert Review of Molecular Diagnostics 2017;17:205-7. [DOI: 10.1080/14737159.2017.1288100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Arrudi-Moreno M, García-Romero R, Samper-Villagrasa P, Sánchez-Malo MJ, Martin-de-Vicente C. Neonatal cystic fibrosis screening: Analysis and differences in immunoreactive trypsin levels in newborns with a positive screen. An Pediatr (Engl Ed) 2021;95:11-7. [PMID: 34140271 DOI: 10.1016/j.anpede.2020.04.022] [Reference Citation Analysis]
8 Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med 2016;4:653-61. [PMID: 27053341 DOI: 10.1016/S2213-2600(16)00053-9] [Cited by in Crossref: 82] [Cited by in F6Publishing: 27] [Article Influence: 13.7] [Reference Citation Analysis]
9 Sicko RJ, Stevens CF, Hughes EE, Leisner M, Ling H, Saavedra-Matiz CA, Caggana M, Kay DM. Validation of a Custom Next-Generation Sequencing Assay for Cystic Fibrosis Newborn Screening. Int J Neonatal Screen 2021;7:73. [PMID: 34842611 DOI: 10.3390/ijns7040073] [Reference Citation Analysis]
10 Rosenfeld M, Sontag MK, Ren CL. Cystic Fibrosis Diagnosis and Newborn Screening. Pediatr Clin North Am. 2016;63:599-615. [PMID: 27469178 DOI: 10.1016/j.pcl.2016.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
11 Sontag MK, Lee R, Wright D, Freedenberg D, Sagel SD. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis. The Journal of Pediatrics 2016;175:150-158.e1. [DOI: 10.1016/j.jpeds.2016.03.046] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
12 Januska MN, Marx L, Walker PA, Berdella MN, Langfelder-Schwind E. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. J Genet Couns 2020;29:607-15. [PMID: 32227567 DOI: 10.1002/jgc4.1271] [Reference Citation Analysis]
13 Kay DM, Maloney B, Hamel R, Pearce M, Demartino L, Mcmahon R, Mcgrath E, Krein L, Vogel B, Saavedra-matiz CA, Caggana M, Tavakoli NP. Screening for cystic fibrosis in New York State: considerations for algorithm improvements. Eur J Pediatr 2016;175:181-93. [DOI: 10.1007/s00431-015-2616-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]